Pharmaceuticals · Market research

PD-1 and PD-L1 Inhibitors reports

Coverage across 33 countries and regions. Researched figures and forecasts come with the full report.

Get the full PD-1 and PD-L1 Inhibitors market evidence

The purchased report supplies researched market size, forecast, growth, segments, competition and sources.

Buy the full report Request free sample
PD-1 and PD-L1 Inhibitors reports by place
PlaceCurrent sizeForecastGrowthActive trialsReport
WorldIn full reportIn full reportIn full report1,217View report
AfricaIn full reportIn full reportIn full report19View report
APACIn full reportIn full reportIn full report727View report
AustraliaIn full reportIn full reportIn full report91View report
BrazilIn full reportIn full reportIn full report50View report
CanadaIn full reportIn full reportIn full report85View report
ChinaIn full reportIn full reportIn full report654View report
EcuadorIn full reportIn full reportIn full report0View report
EgyptIn full reportIn full reportIn full report0View report
EuropeIn full reportIn full reportIn full report194View report
FranceIn full reportIn full reportIn full report110View report
GermanyIn full reportIn full reportIn full report92View report
Hong KongIn full reportIn full reportIn full report14View report
IndiaIn full reportIn full reportIn full report11View report
ItalyIn full reportIn full reportIn full report91View report
JapanIn full reportIn full reportIn full report56View report
KenyaIn full reportIn full reportIn full report0View report
Latin AmericaIn full reportIn full reportIn full report57View report
MalaysiaIn full reportIn full reportIn full report15View report
MexicoIn full reportIn full reportIn full report29View report
Middle EastIn full reportIn full reportIn full report3View report
New ZealandIn full reportIn full reportIn full report20View report
North AmericaIn full reportIn full reportIn full report363View report
PhilippinesIn full reportIn full reportIn full report12View report
RussiaIn full reportIn full reportIn full report26View report
Saudi ArabiaIn full reportIn full reportIn full report2View report
SingaporeIn full reportIn full reportIn full report26View report
South AfricaIn full reportIn full reportIn full report17View report
SpainIn full reportIn full reportIn full report117View report
ThailandIn full reportIn full reportIn full report24View report
UAEIn full reportIn full reportIn full report1View report
UKIn full reportIn full reportIn full report82View report
USIn full reportIn full reportIn full report356View report

Public clinical research

1,217 active trials found worldwide on ClinicalTrials.gov.

See the public search

Latest public research

  1. Therapeutic value of PD-1/PD-L1 blockade plus chemotherapy in advanced or metastatic triple-negative breast cancer: a systematic review and meta-analysis of randomized controlled trials.Translational cancer research, 2026
  2. PD-1/PD-L1 inhibitors plus chemotherapy in cervical cancer: A systematic review and meta-analysis.Turkish journal of obstetrics and gynecology, 2026
  3. PD-1/PD-L1 inhibitors in the treatment of pMMR mCRC: a meta-analysis based on randomized controlled trials.Frontiers in oncology, 2026
  4. Efficacy and safety of regorafenib plus PD-1/PD-L1 inhibitors for metastatic colorectal cancer: a systematic review and meta-analysis.World journal of surgical oncology, 2026
  5. Efficacy of anti-PD-1/PD-L1 plus chemotherapy in treatment-naïve advanced HER2-negative gastric adenocarcinoma among different PD-L1 intervals: an updated meta-analysis and reconstructed individual patient-level data analysis.BMC medicine, 2026

Public trial and paper counts come from ClinicalTrials.gov and PubMed. Acuitas market figures are not published on this page.